[Studies on the HBV carriers who became seronegative during the follow-up].

I. Tamura,K. Shimase,H. Ichimura,E. Kaneto,O. Kurimura,H. Tsuchie,T. Kurimura

DOI: https://doi.org/10.11150/kansenshogakuzasshi1970.59.65

Abstract:

What problem does this paper attempt to address?

A target-controlled infusion regimen for reducing remifentanil-induced coughs

Jong-Yeop Kim,Y. Chae,Jin-Soo Kim,Yoon-Jeong Park,S. Min

DOI: https://doi.org/10.4097/kjae.2012.63.1.30

IF: 5.167

2012-07-01

Korean Journal of Anesthesiology

Abstract:Background This study evaluates the effectiveness of the target-controlled infusion (TCI) of remifentanil through stepwise increases in the effect-site concentration (Ceff) in preventing coughs. Methods In a preliminary study, we randomly selected 140 patients to receive remifentanil through two-step increases in Ceff (1.0 ng/ml to 4.0 ng/ml: Group R1-4; 2.0 ng/ml to 4.0 ng/ml: Group R2-4). Based on the results of the preliminary study, we employed another sample of 140 patients and implemented a three-step increase in TCI (1.0 ng/ml to 2.0 ng/ml to 4.0 ng/ml: Group R1-2-4). We then compared this treatment with direct targeting based on 4.0 ng/ml TCI (Group R4). We recorded the episodes of coughs, rating them as mild (1-2), moderate (3-4), or severe (5 or more). Results In Group R1-4, one patient (1.5%) coughed during the first step, and five (7.3%) coughed during the second step. In Group R2-4, nine (13.2%) coughed during the first step, but none coughed during the next step. Only one patient had a mild cough during the three-step increase in TCI, that is, patients in Group R1-2-4 were significantly less likely to cough than those in Group R4 (P < 0.001). Conclusions Stepwise increases in the TCI of remifentanil reduced the incidence of remifentanil-induced coughing, and the three-step increase in TCI nearly eliminated remifentanil-induced coughing.
Impact of Consideration of Transplantation on End-of-Life Care for Patients During a Terminal Hospitalization

A. Walling,S. Asch,K. Lorenz,N. Wenger

DOI: https://doi.org/10.1097/TP.0b013e318277f238

2013-02-27

Transplantation

Abstract:Background Many patients considered for transplantation die before receiving the organ, underlining the importance of providing high-quality symptomatic relief and communication for all transplant patients. Methods To study how consideration of transplantation affects the end-of-life care received by patients, care was evaluated by abstracting medical records for 496 adults who died in one high-volume transplant medical center between April 2005 and April 2006. Sixteen quality indicators from the Assessing Care of Vulnerable Elders set that focused on communication and symptom management were measured to calculate an overall patient-level quality score. We evaluated the predictors of quality of end-of-life care, with the main independent variable being whether the patient was being considered for transplantation. Restricting to patients who died an “expected death,” we also evaluated the end-of-life treatments received. Results Twenty-five percent of decedent patients were considered for transplantation. In adjusted models, patients considered for transplantation received lower-quality end-of-life care, had longer hospital stays before death, and were more likely to receive aggressive life-sustaining treatments. Conclusions Care models should incorporate an emphasis on symptom relief and communication along with transplant preparation.
A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions

Subaina Naeem Khalid,Zeest Ali Khan,Muhammad Hamza Ali,Talal Almas,Tarek Khedro,Vikneswaran Raj Nagarajan

DOI: https://doi.org/10.1016/j.amsu.2021.102799

2021-09-04

Abstract:Bullous pemphigoid (BP) is a severe autoimmune blistering skin disorder that primarily causes disease in the older population and is the most prevalent subepidermal variant of the pemphigoid diseases. It manifests as exquisitely pruritic vesiculobullous eruptions and is associated with significant morbidity and mortality. Studies are reporting an increase in prevalence, and, among the elderly, BP is no longer considered to be as rare as previously thought. The pathogenesis involves autoantibodies directed against proteinaceous components of hemidesmosomes, with consequent autoimmune destruction of the dermal-epidermal junction. In recent times, more complex elements of the underlying inflammatory orchestra have been elucidated and are being used to develop targeted immunotherapies. The primary treatment modalities of BP include the use of topical and systemic corticosteroids, certain non-immunosuppressive agents (tetracyclines, nicotinamide, and sulfone), and immunosuppressants (methotrexate, azathioprine, cyclophosphamide, and Mycophenolate). However, in the long term, most of these agents are associated with substantial toxicities while recurrence rates remain high. Such egregious prospects led to significant efforts being directed towards developing newer targeted therapies which work by attenuating specific newly discovered pillars of the inflammatory pathway, and these efforts have garnered hope in providing safer alternatives. Our review focuses on presenting the various therapeutic options that are currently in trial since December 2019, as well as on summarizing presently established treatment guidelines to provide readers with the latest exciting updates.
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

L. Borradori,N. Van Beek,C. Feliciani,B. Tedbirt,E. Antiga,R. Bergman,B. C. Böckle,M. Caproni,F. Caux,N.S. Chandran,G. Cianchini,M. Daneshpazhooh,D. De,D. Didona,G. M. Di Zenzo,M. Dmochowski,K. Drenovska,J. Ehrchen,M. Goebeler,R. Groves,C. Günther,B. Horvath,M. Hertl,S. Hofmann,D. Ioannides,B. Itzlinger‐Monshi,J. Jedličková,C. Kowalewski,K. Kridin,Y. L. Lim,B. Marinovic,A. Marzano,J.‐M. Mascaro,J.M. Meijer,D. Murrell,K. Patsatsi,C. Pincelli,C. Prost,K. Rappersberger,M. Sárdy,J. Setterfield,M. Shahid,E. Sprecher,K. Tasanen,S. Uzun,S. Vassileva,K. Vestergaard,A. Vorobyev,I. Vujic,G. Wang,K. Wozniak,S. Yayli,G. Zambruno,D. Zillikens,E. Schmidt,P. Joly

DOI: https://doi.org/10.1111/jdv.18220

2022-06-30

Journal of the European Academy of Dermatology and Venereology

Abstract:Background Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo‐like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence‐based or rely on expert opinion. The degree of consent among all task force members was included. Results Treatment depends on the severity of BP and patients' comorbidities. High‐potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B‐cell‐depleting therapy and intravenous immunoglobulins may be considered in treatment‐resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions The guidelines for the management of BP were updated. They summarize evidence‐ and expert‐based recommendations useful in clinical practice.

dermatology
Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid

Silke C Hofmann,Ocko Kautz,Michael Hertl,Michael Sticherling,Detlef Zillikens,Leena Bruckner-Tuderman

DOI: https://doi.org/10.1111/j.1610-0387.2008.06872.x

Abstract:Background: The lack of controlled trials on the treatment of pemphigus and pemphigoid diseases limits an evidence-based therapy of these disorders.The aim of this survey was to assess the current treatment standards at German dermatological hospitals and the need for future therapeutic trials. Methods: A two-page questionnaire was sent to 42 German academic and non-academic dermatological hospitals and evaluated at the Department of Dermatology, University Medical Center, Freiburg. Results: The response rate was 76%. Topical clobetasol propionate treatment was regarded as first line therapy of bullous pemphigoid in 27% of the hospitals. More than 50% used systemic corticosteroids at an initial dose of < or = 1 mg/kg prednisolone-equivalent in pemphigus and pemphigoid. Azathioprine is used as first line adjuvant in pemphigoid and pemphigus treatment in 69% and 81% of the hospitals, respectively. Dapsone and mycophenolate mofetil represent alternative options, as well as cyclophosphamide-dexamethasone-pulse therapy in pemphigus. Immunosuppressive treatment of pemphigoid and pemphigus is terminated by 58% and 46% of the hospitals 1-3 months after clinical remission, respectively, but the given time points appeared to be variable. Conclusions: The high response rate to this survey demonstrates the interest in this topic. The variability of the answers regarding initial doses of corticosteroids and time points for termination of therapy indicates the need for the establishment of guidelines and for controlled therapeutic trials.
Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options

Nina van Beek,Detlef Zillikens,Enno Schmidt

DOI: https://doi.org/10.3238/arztebl.m2021.0136

2021-06-18

Abstract:Background: Bullous autoimmune dermatoses are a clinically and immunopatho - logically heterogeneous group of diseases, characterized clinically by blisters or erosions of the skin and/or mucous membranes. In Germany, their prevalence is approximately 40 000 cases nationwide, and their incidence approximately 20 new cases per million people per year. Methods: This review is based on publications that were retrieved by a selective search of the literature focusing on the current German and European guidelines. Results: Recent years have seen the publication of guidelines, controlled prospective clinical trials, and multicenter diagnostic studies improving both diagnosis and therapy. Specific monovalent and multivariate serological test systems and pattern analysis of tissue-bound autoantibodies allow identification of the target antigens in 80-90% of patients. This enables the precise classification of disease entities, with implications for treatment selection and disease outcome. In 2019, the anti-CD20 antibody rituximab was approved by the European Medicines Agency for the treatment of moderate and severe pemphigus vulgaris, with an ensuing marked improvement in the care of the affected patients. To treat mild and moderate bullous pemphigoid, topical clobetasol proprionate is recommended, in severe disease, combined with systemic treatment, i.e. usually (a) prednisolone p.o. at an initial dose of 0.5mg/kg/d , (b) an immunomodulant, e.g. dapsone or doxycycline, or (c) prednisolone plus an immunomodulant. Conclusion: The early recognition and precise diagnostic evaluation of bullous autoimmune dermatoses now enables improved, often interdisciplinary treatment, in accordance with the available guidelines. Current research projects are focused on new treatment approaches, an improved understanding of the underlying pathophysiology, and further refinements of diagnostic techniques.
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Meropi Karakioulaki,Kilian Eyerich,Aikaterini Patsatsi

DOI: https://doi.org/10.1007/s40257-023-00832-1

Abstract:Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
Evidence-based management of bullous pemphigoid

Benjamin S Daniel,Luca Borradori,Russell P Hall 3rd,Dédée F Murrell

DOI: https://doi.org/10.1016/j.det.2011.06.003

Abstract:Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease typically affecting the elderly. Although different therapeutic regimens have been proposed, a review of the evidence is needed to aid clinicians in their decision making and management. Systemic therapies such as corticosteroids and adjuvants are effective in BP but are plagued with adverse effects, and potent topical steroids are an alternative treatment. This article reviews the evidence supporting different therapeutic options in the management of BP.
Innate Immune Responses to Lung-Stage Helminth Infection Induce Alternatively Activated Alveolar Macrophages

Joshua J. Reece,M. Siracusa,A. Scott

DOI: https://doi.org/10.1128/IAI.00687-06

2006-09-01

Infection and Immunity

Abstract:ABSTRACT While it is well established that infection with the rodent hookworm Nippostrongylus brasiliensis induces a strongly polarized Th2 immune response, little is known about the innate host-parasite interactions that lead to the development of this robust Th2 immunity. We exploited the transient pulmonary phase of N. brasiliensis development to study the innate immune responses induced by this helminth parasite in wild-type (WT) and severe-combined immune deficient (SCID) BALB/c mice. Histological analysis demonstrated that the cellular infiltrates caused by N. brasiliensis transit through the lungs were quickly resolved in WT mice but not in SCID mice. Microarray-based gene expression analysis demonstrated that there was a rapid induction of genes encoding molecules that participate in innate immunity and in repair/remodeling during days 2 to 4 postinfection in the lungs of WT and SCID mice. Of particular note was the rapid upregulation in both WT and SCID mice of the genes encoding YM1, FIZZ1, and Arg1, indicating a role for alternatively activated macrophages (AAMs) in pulmonary innate immunity. Immunohistochemistry revealed that nearly all alveolar macrophages became YM1-producing AAMs as early as day 2 postinfection. While the innate responses induced during the lung phase of N. brasiliensis infection were similar in complexity and magnitude in WT and SCID mice, only mice with functional T cells were capable of maintaining elevated levels of gene expression beyond the innate window of reactivity. The induction of alternatively activated alveolar macrophages could be important for dampening the level of inflammation in the lungs and contribute to the long-term decrease in pulmonary inflammation that has been associated with helminth infections.
Performance of lactating dairy cows fed silage from corn of varying maturities.

N. S. St Pierre,R. Bouchard,G. St Laurent,G. L. Roy,C. Vinet

DOI: https://doi.org/10.3168/JDS.S0022-0302(87)79985-8

IF: 4.225

Journal of Dairy Science

Abstract:The deleterious effect of frost on corn harvested for silage was investigated with 30 lactating Holstein cows fed silages from corn harvested at the milk or dough stage, or after one, two, or five frosts. The fibrous components of the corn plant increased as maturity and dry matter content increased, whereas the mineral content tended to decrease. Dry matter intake and 4% fat-corrected milk increased as maturity of the silage increased up to the silage harvested after two frosts and then declined for the silage harvested after five frosts. Gross energy apparent digestibility decreased from 64.9% for milk stage silage to 60.6% for silage from corn harvested after five frosts. Partitioning of gross energy, nitrogen, calcium, phosphorus, potassium, and magnesium provided similar increasing trends in feed intake, utilization, and milk production from milk stage silage to that harvested after two frosts, then a decline of all measurements occurred with silage harvested after five frosts. Net energy for lactation was calculated for each silage from the observed digestible energy, from a regression equation used by the provincial feed evaluation laboratories, and from a recently published summative equation; the latter method appeared best.
To Cut is to Cure: The Surgeon's Role in Improving Value

J. Jopling,Clifford C. Sheckter,B. James

DOI: https://doi.org/10.1097/SLA.0000000000002596

IF: 13.787

2017-11-01

Annals of Surgery

Abstract:SURGEONS WILL INCREASINGLY BEAR FINANCIAL RISK WITH NEW PAYMENT MODELSValue-based reimbursement is supplanting traditional fee-for-service payment. Forward thinking payers, providers, and patients are redesigning care delivery to maximize patient experience and population-level health at an affordab
Transfer and Expression of a Multiple Antibiotic Resistance Plasmid in Marine Bacteria

S. Chandrasekaran,B. Venkatesh,D. Lalithakumari

DOI: https://doi.org/10.1007/s002849900390

IF: 2.343

1998-11-01

Current Microbiology

Abstract:
[Management of bullous pemphigoid and mucous membrane pemphigoid]

Johannes S Kern,Silke C Hofmann

DOI: https://doi.org/10.1007/s00105-023-05241-3

Abstract:Background: Bullous pemphigoid (BP) is the most common blistering autoimmune dermatosis and, as an age-associated disease, is also the bullous dermatosis with the highest increase in incidence in recent years due to demographic developments. Mucous membrane pemphigoid (MMP), which is less common, is a clinically and immunopathologically heterogeneous blistering autoimmune dermatosis characterized by blisters and erosions on mucous membranes. Objective: This work summarizes the manifold clinical characteristics of both diseases and provides an up-to-date overview of diagnostics and therapy of BP and SHP. Materials and methods: A selective literature search was carried out. Results: While eczematous, urticarial, or bullous lesions on the integument are typical for BP, MMP is characterized by pronounced, erosive mucosal changes orally, ocularly, genitoanally, tracheally or esophageally and, at most, only minor skin involvement. For diagnosis, the combination of histology, direct immunofluorescence microscopy, and serological detection of autoantibodies against the hemidesmosomal proteins BP180 and BP230 and, in MMP, also against laminin 332 is important. New pathophysiological findings and therapeutics have recently significantly expanded the range of treatment options. Conclusion: Due to the comorbidities of the usually elderly BP patients and the often multiple affected mucous membranes in MMP, with the risk of developing irreversible complications such as strictures and synechiae, interdisciplinary diagnosis and therapy is often required.
Prevalence and genotypes of Giardia duodenalis in 1-2 year old dairy cattle.

J. Trout,M. Santín,E. Greiner,R. Fayer

DOI: https://doi.org/10.1016/J.VETPAR.2006.03.025

IF: 2.821

2006-09-10

Veterinary Parasitology

Abstract:
A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets

Mohsen Afarideh,Robert Borucki,Victoria P Werth

DOI: https://doi.org/10.3390/jcm11102856

2022-05-18

Abstract:Bullous pemphigoid (BP) is a rare, chronic antibody-mediated autoimmune blistering disease primarily affecting the elderly, with an age of onset over 60. Current treatment options are limited and involve the use of corticosteroids and immunosuppressants, but their long-term use is associated with significant morbidity and mortality. In Japan, human intravenous immunoglobin is approved for the treatment of corticosteroid-refractory BP. However, no treatment option is approved by the Food and Drug Administration for the management of BP. Therefore, developing effective therapies free of debilitating side effects is imperative. In this review, we summarize the main immunologic pathways involved in the pathogenesis of BP, with an emphasis on the role of eosinophils, immunoglobulins, cytokines such as the interleukin (IL)-4 and IL-5, and complements. We further discuss the latest advances with novel therapeutic targets tested for the management of BP. Ongoing efforts are needed to run well-designed controlled trials and test the efficacy and safety of investigational drugs while providing much-needed access to these medications for refractory patients who will not otherwise be able to afford them as off-label prescriptions.
[Bullous pemphigoid: diagnostics and new therapeutic strategies]

S C Hofmann,L Bruckner-Tuderman

DOI: https://doi.org/10.1055/s-2006-932531

2006-02-24

Abstract:Bullous pemphigoid, the most frequent bullous autoimmune dermatosis of the adult, typically presents as disseminated tense blisters on normal or erythematous skin. The diagnosis can be confirmed by direct and indirect immunofluorescence, the detection of circulating autoantibodies against the basement membrane proteins collagen XVII/BP180 and BP230, and histopathology. Autoantibody reactivity against collagen XVII can be measured by ELISA and correlates with disease activity. The ELISA therefore provides a useful tool for monitoring disease activity. Treatment of bullous pemphigoid usually consists of topical and / or systemic steroids in combination with immunosuppressive agents. The intensity of skin involvement and the concurrent diseases and medications of the patient must be considered when selecting a certain treatment. Interdisciplinary cooperation between general practitioners, internists and other specialists facilitates the optimal adaptation of the medication and the early discovery of potential side effects.
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Victoria P. Werth,Dédée F. Murrell,Pascal Joly,Renata Heck,Jamie M. Orengo,Marius Ardeleanu,Verena Hultsch

DOI: https://doi.org/10.1007/s12325-024-02992-w

2024-11-11

Advances in Therapy

Abstract:Bullous pemphigoid (BP) is an autoimmune blistering disease that most often affects elderly individuals and has a significant negative impact on quality of life. The disease is characterized primarily by autoantibodies to hemidesmosomal proteins BP180 and/or BP230, and an inflammatory reaction with notable features of type 2 inflammation, including elevated serum IgE, increased numbers of eosinophils in lesions and peripheral blood, and elevated expression of type 2 cytokines and chemokines in skin lesions. In this review, we present what is known about BP pathophysiology, including the role of type 2 inflammation, and discuss how findings from studies of biologics targeting type 2 immune mediators have helped to clarify the biological mechanisms driving BP pathophysiology. Future studies of these targeted therapies and others in development will help to further elucidate the mechanisms underlying BP pathophysiology and potentially provide better treatment options for patients.

pharmacology & pharmacy,medicine, research & experimental
Functional significance of climbing-fiber synchrony: a population coding and behavioral analysis.

J. Welsh

IF: 6.499

Annals of the New York Academy of Sciences

Abstract:Population coding and behavioral approaches were taken toward analyzing the functional significance of the climbing-fiber system. Analyses of neuronal interaction using the joint peristimulus time histogram showed that given a low rate of firing, the climbing-fiber system organizes itself to fire synchronously during movement--a feature that bears little or no relationship to the modulation in firing rate during movement or whether olivary neurons respond to a sensory stimulus. Moreover, the climbing-fiber system avoids synchrony during a passive sensory response but actively makes a transition into synchrony as a movement is initiated. Thus, from a functional viewpoint, the active feature of the climbing-fiber system to organize into synchronously firing cell ensembles is uniquely motor. Analyses of behaving rats without an inferior olive revealed that the climbing-fiber system optimizes the timing of skilled movement by reducing reaction time and the interval between repetitive movements by 100 milliseconds. Finally, using classical delay eyeblink conditioning, it was found that the inferior olive is essential for learning about rapid sequences of events but not the same event sequence when given more slowly. It was concluded that the climbing-fiber system exerts its function through synchrony, which provides a 100 ms advantage in movement speed and the ability to learn about events that are rapidly presented in time.
Antibacterial drug discovery in the 21st century.

K. Bush

DOI: https://doi.org/10.1111/J.1465-0691.2004.1005.X

IF: 13.31

Clinical Microbiology and Infection

Abstract:Antibacterial research over the past 50 years has been focused on meeting medical needs caused by infectious, life-threatening pathogens. In spite of the introduction of a variety of antibacterial agents in multiple unrelated drug classes, resistance continues to emerge. The pharmaceutical industry must respond to these clinical challenges by bringing forward a stream of new agents with antibacterial activity against resistant bacteria. Although the projected growth of the anti-infective area may not be as large as for some therapeutic areas, development advantages for these agents include their higher predictability for success, well-defined biomarkers, shorter clinical trials, and shorter duration of therapy leading to fewer long-term safety concerns. Anti-infectives are still attractive commercially, representing the third largest therapeutic area in terms of worldwide sales of 45 bn dollars, with growth predicted at least through 2010, particularly for the hospital-related products. Finally, companies that conduct anti-infective research demonstrate their social responsibility by developing agents to treat patients with acute and potentially fatal illnesses.
Black Chromosome 4 Interval Zealandin B 6 Mice with an Introgressed New Autoantibody Production and Renal Disease B 1 a and NKT Cell Expansions from Dissociation of the Genetic Loci

C. Loh,Yong-chun Cai,G. Bonventi,G. Lajoie,Ralph MacLeod,J. Wither

Abstract:

[Studies on the HBV carriers who became seronegative during the follow-up].

A target-controlled infusion regimen for reducing remifentanil-induced coughs

Impact of Consideration of Transplantation on End-of-Life Care for Patients During a Terminal Hospitalization

A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid

Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options

Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update

Evidence-based management of bullous pemphigoid

Innate Immune Responses to Lung-Stage Helminth Infection Induce Alternatively Activated Alveolar Macrophages

Performance of lactating dairy cows fed silage from corn of varying maturities.

To Cut is to Cure: The Surgeon's Role in Improving Value

Transfer and Expression of a Multiple Antibiotic Resistance Plasmid in Marine Bacteria

[Management of bullous pemphigoid and mucous membrane pemphigoid]

Prevalence and genotypes of Giardia duodenalis in 1-2 year old dairy cattle.

A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets

[Bullous pemphigoid: diagnostics and new therapeutic strategies]

Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)

Functional significance of climbing-fiber synchrony: a population coding and behavioral analysis.

Antibacterial drug discovery in the 21st century.

Black Chromosome 4 Interval Zealandin B 6 Mice with an Introgressed New Autoantibody Production and Renal Disease B 1 a and NKT Cell Expansions from Dissociation of the Genetic Loci